Nifty near 14000 mark- Market in consolidation mode sakshi.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sakshi.com Daily Mail and Mail on Sunday newspapers.
Exclusive content, features, opinions and comment - hand-picked by our editors, just for you.
Pick 5 of your favourite companies. Get a daily email with all the news updates on them.
Track the industry of your choice with a daily newsletter specific to that industry.
Stay on top of your investments. Track stock prices in your portfolio.
NOTE :
This product is a monthly auto renewal product.
Cancellation Policy: You can cancel any time in the future without assigning any reasons, but 48 hours prior to your card being charged for renewal. We do not offer any refunds.
To cancel, communicate from your registered email id and send the mail with the request to assist@bsmail.in. Include your contact number for easy reference. Requests mailed to any other ID will not be acknowledged or actioned upon.
NEW DELHI (dpa-AFX) - Aurobindo Pharma said it has obtained the exclusive rights to develop, manufacture and sell US-based company COVAXX's COVID-19 vaccine candidate, UB-612, in India and to
Hauppauge, New York (Newsfile Corp. - December 24, 2020) - COVAXX, a U.S. company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo